title: [Effect of ligustrazine on proliferative glomerulonephritis].
abstract: OBJECTIVE
  To investigate the therapeutic effect of ligustrazine on proliferative nephritis.
  
  
  METHODS
  45 patients with mesangial cell proliferation were randomly divided into two groups according to age, clinical manifestations and the pathological lesions. Steroid, cyclophosphamide, losartan and dipyridamole were given to 20 patients in the control group. Ligustrazine with the dosage of 80 mg twice a day was given to 25 patients in the treatment group by intravenous perfusion besides the medicine used in the control group. The course of ligustrazine treatment lasted three weeks.
  
  
  RESULTS
  The proteinuria and hematuria were decreased significantly with the increases of urine volume, serum albumin and creatinine clearance after ligustrazine treatment. The improvement of serum albumin, proteinuria and hematuria in the treated group were significant compared with control group after treatment.
  
  
  CONCLUSIONS
  Ligustrazine is eutherapeutic in treating proliferative glomerulonephritis, with the less risk of hemorrhage, ligustrazine can be used for long-term treatment without special monitored.
authors.affiliation: Zhujiang Hospital, First Military Medical University, Guangzhou 510280.
authors.forename: Xun
authors.initials: X
authors.lastname: Tang
mesh_terms: D000293:Adolescent; D000328:Adult; D003404:Creatinine / Q000097:blood; D003520:Cyclophosphamide / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005343:Fibrinolytic Agents / Q000302:isolation & purification / Q000627:therapeutic use*; D005922:Glomerulonephritis, IGA / Q000097:blood / Q000188:drug therapy; D015432:Glomerulonephritis, Membranoproliferative / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D019808:Losartan / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D011719:Pyrazines / Q000302:isolation & purification / Q000627:therapeutic use*; D012709:Serum Albumin / Q000378:metabolism
chemical_list: D005343:Fibrinolytic Agents; D011719:Pyrazines; D012709:Serum Albumin; D004176:Dipyridamole; D003520:Cyclophosphamide; D003404:Creatinine; D019808:Losartan; C017953:tetramethylpyrazine; D011241:Prednisone